Future studies are warranted to establish this link (cause-consequence) between reduced cMyBP-C protein levels, increased α-tubulin acetylation and cardiomyocyte contractile function and hypertrophy that may underlie initiation and progression of cardiac disease in MYBPC3 mutation carriers. This evidence concerns the gene MYBPC3 and heart disorder.